Semaglutide has shown some potential benefits for the liver, especially in people with non-alcoholic fatty liver disease (NAFLD)
Imtiaz B, Tuppurainen M, Rikkonen T, Kivipelto M, Soininen H, Krger H, et al
Metformin with tirzepatide is one of the most common pharmaceutical combinations
In these cases, provider evaluation must address whether baseline thyroid function is stable, TSH is well-controlled, and whether introducing a GLP-1 agent poses any incremental autoimmune risk for that individual
ABSTRACT INTRODUCTION GLUCAGON GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE GLUCAGON-LIKE PEPTIDE-1 DUAL GLUCAGON/GLUCAGON-LIKE PEPTIDE-1 RECEPTOR CO-AGONISTS DUAL GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON-LIKE PEPTIDE-1 RECEPTOR CO-AGONISTS TRIPLE GLUCAGON-LIKE PEPTIDE-1/GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON RECEPTOR TRIAGONISTS CONCLUSIONS Article information References ABSTRACT Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide
It is worth noting that not all beta-blockers affect sexual function equally